Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort
التفاصيل البيبلوغرافية
العنوان:
Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort